
EquitySector - HealthcareVery High Risk
Regular
NAV (16-Jan-26)
Returns (Since Inception)
Fund Size
₹6,456 Cr
Expense Ratio
1.86%
ISIN
INF109KC1GE9
Minimum SIP
₹1,000
Exit Load
1.00%
Inception Date
12 Jul 2018
In this section, we compare the returns of the scheme with the category average over various periods. Periods for which the fund has outperformed its category average are marked in green, otherwise red.
1 Year
+1.79%
+1.13% (Cat Avg.)
3 Years
+26.37%
+22.11% (Cat Avg.)
5 Years
+16.51%
+14.61% (Cat Avg.)
Since Inception
+19.73%
— (Cat Avg.)
| Equity | ₹6,318.14 Cr | 97.87% |
| Others | ₹137.41 Cr | 2.13% |
All Holdings
Equity
Debt & Others
| Name | Type | Amount | Holdings |
|---|---|---|---|
| Sun Pharmaceuticals Industries Ltd | Equity | ₹777.92 Cr | 12.05% |
| Cipla Ltd | Equity | ₹509.92 Cr | 7.90% |
| Dr Reddy's Laboratories Ltd | Equity | ₹505.14 Cr | 7.82% |
| Divi's Laboratories Ltd | Equity | ₹458.33 Cr | 7.10% |
| Mankind Pharma Ltd | Equity | ₹415.63 Cr | 6.44% |
| Lupin Ltd | Equity | ₹373.31 Cr | 5.78% |
| Aurobindo Pharma Ltd | Equity | ₹335.21 Cr | 5.19% |
| Alkem Laboratories Ltd | Equity | ₹236.4 Cr | 3.66% |
| Cohance Lifesciences Ltd | Equity | ₹194.11 Cr | 3.01% |
| Syngene International Ltd | Equity | ₹192.44 Cr | 2.98% |
| Zydus Lifesciences Ltd | Equity | ₹161.04 Cr | 2.49% |
| Alivus Life Sciences Ltd | Equity | ₹144.51 Cr | 2.24% |
| Treps | Cash - Repurchase Agreement | ₹134.9 Cr | 2.09% |
| Thyrocare Technologies Ltd | Equity | ₹125 Cr | 1.94% |
| Alembic Pharmaceuticals Ltd | Equity | ₹122.13 Cr | 1.89% |
| Akums Drugs and Pharmaceuticals Ltd | Equity | ₹110.63 Cr | 1.71% |
| Medi Assist Healthcare Services Ltd | Equity | ₹110.62 Cr | 1.71% |
| J.B. Chemicals & Pharmaceuticals Ltd | Equity | ₹105.31 Cr | 1.63% |
| Gland Pharma Ltd | Equity | ₹99 Cr | 1.53% |
| Entero Healthcare Solutions Ltd | Equity | ₹98.7 Cr | 1.53% |
| Pfizer Ltd | Equity | ₹90.26 Cr | 1.40% |
| Medplus Health Services Ltd | Equity | ₹86.47 Cr | 1.34% |
| Blue Jet Healthcare Ltd | Equity | ₹84.97 Cr | 1.32% |
| Metropolis Healthcare Ltd | Equity | ₹84.52 Cr | 1.31% |
| Glenmark Pharmaceuticals Ltd | Equity | ₹77.1 Cr | 1.19% |
| Hikal Ltd | Equity | ₹72.95 Cr | 1.13% |
| Aarti Drugs Ltd | Equity | ₹70.88 Cr | 1.10% |
| Fine Organic Industries Ltd Ordinary Shares | Equity | ₹70.14 Cr | 1.09% |
| Anthem Biosciences Ltd | Equity | ₹68.58 Cr | 1.06% |
| Windlas Biotech Ltd | Equity | ₹68.19 Cr | 1.06% |
| Shilpa Medicare Ltd | Equity | ₹61.86 Cr | 0.96% |
| Sanofi Consumer Healthcare India Ltd | Equity | ₹55.62 Cr | 0.86% |
| Laxmi Dental Ltd | Equity | ₹54.17 Cr | 0.84% |
| Senores Pharmaceuticals Ltd | Equity | ₹52.69 Cr | 0.82% |
| FDC Ltd | Equity | ₹50.67 Cr | 0.78% |
| AstraZeneca Pharma India Ltd | Equity | ₹49.68 Cr | 0.77% |
| Rubicon Research Ltd | Equity | ₹49.13 Cr | 0.76% |
| Procter & Gamble Health Ltd | Equity | ₹40.76 Cr | 0.63% |
| Sun Pharma Advanced Research Co Ltd | Equity | ₹28.68 Cr | 0.44% |
| Nephrocare Health Services Ltd | Equity | ₹25.47 Cr | 0.39% |
| Cash Margin - Derivatives | Cash - Collateral | ₹8.41 Cr | 0.13% |
| Net Current Assets | Cash | ₹-5.9 Cr | 0.09% |
Large Cap Stocks
34.87%
Mid Cap Stocks
25.83%
Small Cap Stocks
37.17%
Equity Sector
Debt & Others
| Sector | Amount | Holdings |
|---|---|---|
| Healthcare | ₹6,248 Cr | 96.78% |
| Basic Materials | ₹70.14 Cr | 1.09% |
Standard Deviation
This fund
15.54%
Cat. avg.
15.84%
Lower the better
Sharpe Ratio
This fund
1.24
Cat. avg.
0.98
Higher the better
Sortino Ratio
This fund
--
Cat. avg.
1.79
Higher the better
Since May 2020
Since July 2022
ISIN INF109KC1GE9 | Expense Ratio 1.86% | Exit Load 1.00% | Fund Size ₹6,456 Cr | Age 7 years 6 months | Lumpsum Minimum ₹5,000 | Fund Status Open Ended Investment Company | Benchmark BSE Healthcare TR INR |
To seek to generate long-term capital growth from an actively managed portfolio primarily of Equity and Equity Related Securities. Scheme shall invest in Indian equities,foreign equities and related instruments and debt securities.
Note: As per the Income Tax Budget 2024, mutual funds are subject to capital gains taxation, which includes surcharge and cess based on prevailing income tax rules and the investor’s income. Taxation applies only to realised gains, not notional gains. Please consult your tax advisors to determine the implications or consequences of your investments in such securities.

Total AUM
₹11,35,842 Cr
Address
3rd Floor, Hallmark Business Plaza, Mumbai, 400 051
Your principal amount will be at Very High Risk

Download Dezerv App
Track and monitor all
your investments